Cambridge Investment Research Advisors
OCUL icon

Cambridge Investment Research Advisors’s Ocular Therapeutix OCUL Stock Holding History

Cambridge Investment Research Advisors’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$483K Buy
57,074
+18,615
+48% +$177K ﹤0.01% 2837
2025
Q4 		$467K Buy
38,459
+9,359
+32% +$114K ﹤0.01% 2788
2025
Q3 		$340K Buy
29,100
+5,000
+21% +$59.8K ﹤0.01% 3006
2025
Q2 		$224K Buy
+24,100
New +$189K ﹤0.01% 3245

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Cambridge Investment Research Advisors's OCUL Position: Q1 2026 in Review

Cambridge Investment Research Advisors increased its Ocular Therapeutix (OCUL) stake by 48% in Q1 2026, buying an estimated $177K and bringing the position to 57,074 shares worth $483K. The position accounts for ﹤0.01% of the portfolio, ranked #2837.

Cambridge Investment Research Advisors first reported a position in OCUL in Q2 2025 and has held it in 4 quarters since. 269 funds tracked by Wall St. Rank hold OCUL as of Q1 2026.

  • Cambridge Investment Research Advisors held 57,074 shares of Ocular Therapeutix worth $483K as of Q1 2026.
  • Cambridge Investment Research Advisors bought 18,615 Ocular Therapeutix shares in Q1 2026, an estimated $177K.
  • Ocular Therapeutix made up ﹤0.01% of Cambridge Investment Research Advisors's portfolio in Q1 2026, its #2837 holding.
  • Cambridge Investment Research Advisors first reported a position in Ocular Therapeutix in Q2 2025 and has held it in 4 quarters since.
  • 269 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q1 2026.

Based on Cambridge Investment Research Advisors's 13F filing for Q1 2026, filed 30 Apr 2026.